Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ERJ Open Res
Main Authors: Castro, Mario, Rabe, Klaus F., Corren, Jonathan, Pavord, Ian D., Katelaris, Constance H., Tohda, Yuji, Zhang, Bingzhi, Rice, Megan S., Maroni, Jaman, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Akinlade, Bolanle, Graham, Neil M.H., Teper, Ariel
Formato: Artigo
Idioma:Inglês
Publicado em: European Respiratory Society 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983496/
https://ncbi.nlm.nih.gov/pubmed/32010719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00204-2019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados